Background and Importance Migraine affects 15% of the world’s population so is necessary to carry out interventions to help improve the quality of life of patients.
Aim and Objectives Evaluation of quality of life in migraine patients treated with erenumab or galcanezumab before administration, three months after and one year later.
Material and Methods Retrospective study conducted in a hospital by EQ-5D-5L questionnaires before drug administration, three months and one year later. The following data were collected: sex, age, educational level and quality of life dimensions (mobility, self-care, activities of daily living, pain/discomfort and anxiety/depression). Patients completed the visual analogue scale (VAS), graduated from 0 (worst condition) to 10.
Results Of the 67 patients, 45 completed the questionnaire after three months. 16 patients discontinued treatment before one year, so the percentage of surveys received was 50%. Mean age 48.9 years (85.1% women). 37.3% had higher education and 43.3% primary or secondary education. The rest did not provide data.
-Mobility dimension 76.1% described mild symptoms and 2.98% severe. After three months: 55.22% and 2.8%. One year later, mild symptoms decreased (28.87%).
-Mild self-care symptoms were described by 91.1% and severe by 2.98%. Three months later: 52.23% mild symptoms. One year later: 37.31% and 0%.
-35.8% reported mild problems in performing daily activities and 22.38% showed severity. Three months later, 13.4% continued with severe problems. At one year, mild symptoms: 29.9%.
-Pain/discomfort severe symptoms were 68.6%, three months later 25.4% and one year later 4.5%. Mild symptoms did not improve.
-Severe anxiety/depression initially 26.9%. Three months later 13.4% and one year 6%. Mild symptoms decreased from 52.2% to 23.9% at one year.
On the VAS scale, a median of 5 was obtained at the beginning of treatment compared to 6.25 three months later and 7 one year later.
Conclusion and Relevance “Pain/discomfort’’ and ‘’depression/anxiety’’ are the most affected dimensions.
After three months and after one year, ‘’pain/discomfort’’ was the most improved and ‘’activities of daily living’’ was not affected.
The VAS scale showed an increase in quality of life after three months by a median of 1.25 points and 2 points after one year.
This questionnaire helps us to assess the patients‘ perspective, although we do not yet have the total number of surveys.
Conflict of Interest No conflict of interest